Биомаркеры мочи при раке мочевого пузыря: обзор текущего состояния и будущих направлений

Биомаркеры мочи при раке мочевого пузыря: обзор текущего состояния и будущих направлений

Автор: Солодкий В.А., Павлов А.Ю., Дзидзария А.Г., Самусевич В.А., Гафанов Р.А.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры, лекции

Статья в выпуске: 3 т.21, 2021 года.

Бесплатный доступ

Статья содержит все последние доступные сведения, касающиеся достижений в области биомаркеров рака мочевого пузыря. В ней рассказывается о возможности и целесообразности их применения, доступности для выполнения исследований. Показаны особенности и результаты применения тестов на биомаркеры в сравнении с «золотым стандартом» - цитологическим исследованием мочи.

Немышечно-инвазивный рак мочевого пузыря, биомаркеры мочи, цитологическое исследование мочи, диагностика рака мочевого пузыря, послеоперационный контроль пациентов после лечения рака мочевого пузыря

Короткий адрес: https://sciup.org/149139027

IDR: 149139027

Список литературы Биомаркеры мочи при раке мочевого пузыря: обзор текущего состояния и будущих направлений

  • Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. V. 68. No. 6. P. 394-424. DOI: 10.3322/caac.21492.
  • Cambier S., Sylvester R.J., Collette L., et al. EORTC Nomograms and risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol. 2016. V. 69. No. 1. P. 60-69. DOI: 10.1016/j.eururo.2015.06.045.
  • Tan W.S., Rodney S., Lamb B., et al. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016. V. 47. P. 22-31. DOI: 10.1016/j.ctrv.2016.05.002.
  • Reid M.D., Osunkoya A.O., Siddiqui M.T., Looney S.W. Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement. Int J Clin Exp Pathol. 2012. V. 5. No. 9. P. 882-891.
  • Yafi F.A., Brimo F., Steinberg J., et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 2015. V. 33. No. 2. 66.e25-31. DOI: 10.1016/j.urolonc.2014.06.008.
  • Lotan Y., Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003. V. 61. No. 1.P. 109-118. DOI: 10.1016/s0090-4295(02)02136-2.
  • Svatek R.S., Hollenbeck B.K., Holmang S., et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014. V. 66. No. 2. P. 253-262. DOI: 10.1016/j.eururo.2014.01.006.
  • Crosley L.K., Duthie S.J., Polley A.C., et al. Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics. Genes Nutr. 2009. V. 4. No. 2. P. 95-102. DOI: 10.1007/s12263-009-0121-x.
  • Parekh R.S., Kao W.H., Meoni L.A., et al. Reliability of urinary albumin, total protein, and creatinine assays after prolonged storage: the family investigation of nephropathy and diabetes. Clin J Am Soc Nephrol. 2007. V. 2. No. 6. P. 1156-1162. DOI: 10.2215/CJN.01030207.
  • Thomas C.E., Sexton W., Benson K., et al. Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol Biomarkers Prev. 2010. V. 19. No. 4. P. 953-959. DOI: 10.1158/1055-9965.EPI-10-0069.
  • Chou R., Gore J.L., Buckley D., et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med. 2015. V. 163. No. 12. P. 922-931. DOI: 10.7326/M15-0997.
  • Wang Z., Que H., Suo C., et al. Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis. Oncotarget. 2017. V. 8. No. 59. P. 100648-100656. DOI: 10.18632/oncotarget.22065.
  • Ponsky L.E., Sharma S., Pandrangi L., et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol. 2001. V. 166. No. 1. P. 75-78.
  • Guo A., Wang X., Gao L., et al. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: a meta-analysis. Can Urol Assoc J. 2014. V. 8. No. 5-6. P. E347-352. DOI: 10.5489/cuaj.1668.
  • Lokeshwar V.B., Schroeder G.L., Selzer M.G., et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer. 2002. V. 95. No. 1. P. 61-72. DOI: 10.1002/cncr.10652.
  • Sarosdy M.F., Hudson M.A., Ellis W.J., et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology. 1997. V. 50. No. 3. P. 349-353. DOI: 10.1016/s0090-4295(97)00292-6.
  • Heicappell R., Muller M., Fimmers R., Miller K. Qualitative determination of urinary human complement factor H-related protein (hcfHrp) in patients with bladder cancer, healthy controls, and patients with benign urologic disease. Urol Int. 2000. V. 65. No. 4. P. 181-184. DOI: 10.1159/000064872.
  • Pode D., Shapiro A., Wald M., et al. Noninvasive detection of bladder cancer with the BTA stat test. J Urol. 1999. V. 161. No. 2. P. 443-446.
  • Ellis W.J., Blumenstein B.A., Ishak L.M., Enfield D.L. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology. 1997. V. 50. No. 6. P. 882-887. DOI: 10.1016/s0090-4295(97)00508-6.
  • Thomas L., Leyh H., Marberger M., et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem. 1999. V. 45. No. 4. P. 472-477.
  • Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005. V. 66 (6 Suppl. 1). P. 35-63. DOI: 10.1016/j.urology.2005.08.064.
  • Yoder B.J., Skacel M., Hedgepeth R., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007. V. 127. No. 2. P. 295-301. DOI: 10.1309/ADJL7E810U1H42BJ.
  • Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008. V. 26. No. 6. P. 646-651. DOI: 10.1016/j.urolonc.2007.06.002.
  • Sokolova I.A., Halling K.C., Jenkins R.B., et al. The development of a multitarget, multicolor fluo- rescence in situ hybridization assay for the detection of urothelial car- cinoma in urine. J Mol Diagn. 2000. V. 2. No. 3. P. 116-123. DOI: 10.1016/S1525-1578(10)60625-3.
  • Halling K.C., King W., Sokolova I.A., et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000. V. 164. No. 5. P. 1768-1775.
  • Savic S., Zlobec I., Thalmann G.N., et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer. 2009. V. 124. No. 12. 2899-2904. doi: 10.1002/ijc.24258.
  • Mian C., Pycha A., Wiener H., et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol. 1999. V. 161. No. 5. P. 1486-1489. DOI: 10.1016/s0022-5347(05)68934-3.
  • Lodde M., Mian C., Negri G., et al. Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology. 2003. V. 61. No. 1. P. 243-247. DOI: 10.1016/s0090-4295(02)02073-3.
  • Pfister C., Chautard D., Devonec M., et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol. 2003. V. 169. No. 3. P. 921-924. DOI: 10.1097/01.ju.0000048983.83079.4c.
  • Davis N., Mor Y., Idelevich P., et al. A novel urine cytology stain for the detection and monitoring of bladder cancer. J Urol. 2014. V. 192. No. 6. P. 1628-1632. DOI: 10.1016/j.juro.2014.06.079.
  • Davis N., Shtabsky A., Lew S., et al. A novel urine-based assay for bladder cancer diagnosis: multi-institu- tional validation study. Eur Urol Focus. 2018. V. 4. No. 3. P. 388-394. DOI: 10.1016/j.euf.2016.10.004.
  • Pu R.T., Laitala L.E., Clark D.P. Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol. 2006. V. 50. No. 5. P. 499-506. DOI: 10.1159/000326003.
  • Hauser S., Kogej M., Fechner G., et al. Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res. 2013. V. 33. No. 3. P. 779-784.
  • Renard I., Joniau S., van Cleynenbreugel B., et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 2010. V. 58. No. 1. P. 96-104. DOI: 10.1016/j.eururo.2009.07.041.
  • Fantony J.J., Longo T.A., Gopalakrishna A., et al. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer. Cancer Biomark. 2017. V. 18. No. 4. P. 381-387. DOI: 10.3233/CBM-160261.
  • Wang Y., Yu Y., Ye R., et al. An epigenetic bio- marker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese. Oncotarget. 2016. V. 7. No. 3. P. 2754-2764. DOI: 10.18632/oncotarget.6666.
  • van der Heijden A.G., Mengual L., Ingelmo-Torres M., et al. Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clin Epigenetics. 2018. V. 10. Article ID 71. DOI: 10.1186/s13148-018-0496-x.
  • Lucca I., Hofbauer S.L., Haitel A., et al. Urinary expression of genes involved in DNA methylation and his- tone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. Oncol Lett. 2019. V. 18. No. 1. P. 57-62. DOI: 10.3892/ol.2019.10330.
  • Su S.F., de Castro Abreu A.L., Chihara Y., et al. A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res. 2014. V. 20. No. 7. P. 1978-1989. DOI: 10.1158/1078-0432.CCR-13-2637.
  • Roperch J.P., Grandchamp B., Desgrandchamps F., et al. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/ specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer. 2016. V. 16. No. 1. Article ID 704. DOI: 10.1186/s12885-016-2748-5.
  • Liu J., Li Y., Liao Y., et al. High expression of H3K27me3 is an independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomy. Biomed Res Int. 2013. V. 2013. Article ID 390482. DOI: 10.1155/2013/ 390482.
  • Descotes F., Kara N., Decaussin-Petrucci M., et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer. 2017. V. 117. No. 4. P. 583-587. DOI: 10.1038/bjc.2017.210.
  • Beukers W., van der Keur K.A., Kandimalla R., et al. FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study. J Urol. 2017. V. 197. No. 6. P. 1410-1418. DOI: 10.1016/j.juro.2016.12.096.
  • van Kessel K.E., Kompier L.C., de Bekker-Grob E.W., et al. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies. J Urol. 2013. V. 189. No. 5. P. 1676-1681. DOI: 10.1016/j.juro.2012.11.005.
  • van Rhijn B.W., Lurkin I., Kirkels W.J., et al. Microsatellite analysis − DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer. 2001. V. 92. No. 4. P. 768-775. DOI: 10.1002/1097-0142(20010815)92:4-768::aid-cncr1381-3.0.co;2-c.
  • Czerniak B., Chaturvedi V., Li L., et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene. 1999. V. 18. No. 5. P. 1185-1196. DOI: 10.1038/sj.onc.1202385.
  • Knowles M.A., Elder P.A., Williamson M., et al. Allelotype of human bladder cancer. Cancer Res. 1994. V. 54. No. 2. P. 531-538.
  • Fendler A., Stephan C., Yousef G.M., et al. The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016. V. 13. No. 12. P. 734-752. DOI: 10.1038/nrurol.2016.193.
  • Valadi H., Ekstrom K., Bossios A., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007. V. 9. No. 6. P. 654-659. DOI: 10.1038/ncb1596.
  • Kutwin P., Konecki T., Borkowska E.M., et al. Urine miRNA as a potential biomarker for bladder cancer detection - a meta-analysis. Cent European J Urol. 2018. V. 71. No. 2. P. 177-185. DOI: 10.5173/ceju.2018.1605
  • Kim W.T., Jeong P., Yan C., et al. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria. Oncotarget. 2016. V. 7. No. 36. P. 58193-58202. DOI: 10.18632/oncotarget.11277.
  • Kim W.T., Kim Y.H., Jeong P., et al. Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer. Oncotarget. 2018. V. 9. No. 18. P. 14354- 14365. DOI: 10.18632/oncotarget.24436.
  • O’Sullivan P., Sharples K., Dalphin M., et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012. 188. No. 23. P. 741-747. DOI: 10.1016/j.juro.2012.05.003.
  • Lotan Y., O’Sullivan P., Raman J.D., et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 2017. V. 35. No. 8: 531 e15-531.e22. DOI: 10.1016/j.urolonc.2017.03.008.
  • Elia C.D., Pycha A., Folchini D.M., et al. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer. J Clin Pathol. 2019. V. 72. No. 2. P. 140-144. DOI: 10.1136/jclinpath-2018-205393.
  • Pichler R., Fritz J., Tulchiner G., et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int. 2018. V. 121.No. 1. P. 29-37. DOI: 10.1111/bju.14019.
  • van Kessel K.E., Van Neste L., Lurkin I., et al. Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J Urol. 2016. V. 195. No. 3. P. 601-607. DOI: 10.1016/j.juro.2015.08.085.
  • van Kessel K.E., Beukers W., Lurkin I., et al. Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy. J Urol. 2017. 197 (3 Pt. 1). P. 590-595. DOI: 10.1016/j.juro.2016.09.118.
  • Pena M.D.C.R., Springer S.U., Taheri D., et al. Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. Virchows Arch. 2020. V. 476. No. 3. P. 423-429. DOI: 10.1007/s00428-019-02654-1.
  • Batista R., Vinagre J., Prazeres H., et al. Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive Multicenter study. Front Genet. 2019. V. 10. Article ID 1237. DOI: 10.3389/fgene.2019.01237.
  • Witjes J.A., Morote J., Cornel E.B., et al. Performance of the bladder EpiCheck Methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur Urol Oncol. 2018. V. 1. No. 4. P. 307-313. DOI: 10.1016/j.euo.2018.06.011.
  • Yu S., Cao H., Shen B., Feng J. Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget 2015. V. 6. No. 35. P. 37151-37168. DOI: 10.18632/oncotarget.6022.
  • Liang L.G., Kong M.Q., Zhou S., et al. An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer. Sci Rep. 2017. V. 7. Article ID 46224. DOI: 10.1038/srep46224.
  • Lin S.Y., Chang C.H., Wu H.C., et al. Proteome profiling of urinary exosomes identifies alpha 1-antitrypsin and H2B1K as diagnostic and prognostic biomarkers for urothelial carcinoma. Sci Rep. 2016. V. 6. Article ID 34446. DOI: 10.1038/srep34446.
  • Andreu Z., Otta Oshiro R., Redruello A., et al. Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression. Eur J Pharm Sci. 2017. V. 98. P. 70-79. DOI: 10.1016/j.ejps.2016.10.008.
  • Боженко В.К., Кулинич Т.М., Мельникова Н.В., Нестеров П.В. Лабораторная диагностика рака мочевого пузыря. ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России. 2008.
  • Schmitz-Drager B.J., Kuckuck E.C., Zuiverloon T.C., et al. Microhematuria assessment an IBCN consensus-based upon a critical review of current guidelines. Urol Oncol. 2016. V. 34. No. 2. P. 437-451. DOI: 10.1016/j.urolonc.2016.05.030.
  • Benderska-Soder N., Hovanec J., Pesch B., et al. Toward noninvasive follow-up of low-risk bladder cancer - rationale and concept of the UroFollow trial. Urol Oncol. 2020. V. 38. No. 12. P. 886-895. DOI: 10.1016/j.urolonc.2020.01.006.
  • Todenhofer T., Hennenlotter J., Aufderklamm S., et al. Individual risk assessment in bladder cancer patients based on a multi-marker panel. J Cancer Res Clin Oncol. 2013. V. 139. No. 1. P. 49-56. DOI: 10.1007/s00432-012-1297-9.
  • Mengual L., Burset M., Ribal M.J., et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res. 2010. V. 16. No. 9. P. 2624-2633. DOI: 10.1158/1078-0432.CCR-09-3373.
  • Mengual L., Ribal M.J., Lozano J.J., et al. Validation study of a noninvasive urine test for diag- nosis and prognosis assessment of bladder cancer: evidence for improved models. J Urol. 2014. V. 191. No. 1. P. 261-269. DOI: 10.1016/j.juro.2013.06.083.
  • Nilsson B., Wahren B., Esposti P.L., Edsmyr F. Prediction of survival and recurrence in bladder carcinoma. Urol Res. 1982. V. 10. No. 3. P. 109-113. DOI: 10.1007/BF00255951.
  • Wahren B., Nilsson B., Zimmerman R. Urinary CEA for prediction of survival time and recurrence in bladder cancer. Cancer. 1982. V. 50. No. 1. P. 139-145. DOI: 10.1002/1097-0142(19820701)50:1-139::aid-cncr2820500126-3.0.co;2-s.
  • Zimmerman R., Wahren B., Edsmyr F. Assessment of serial CEA determinations in urine of patients with bladder carcinoma. Cancer. 1980. V. 46. P. 1802-1809. DOI: 10.1002/1097-0142(19801015)46:8-1802::aid-cncr2820460818-3.0.co;2-5.
  • Darling H.S., Bellmunt J. Immunotherapy in non-metastatic urothelial cancer: back to the ’future’. Expert Opin Biol Ther. 2019. V. 19. No. 7. P. 685-695. DOI: 10.1080/14712598.2019.1604673.
  • Soria F., Droller M.J., Lotan Y., et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol. 2018. V. 36. No. 12. P. 1981-1995. DOI: 10.1007/s00345-018-2380-x.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp